All In Biotech

Drug Trial Radar · NCT06659640

A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

InsigHHT: A Phase 1/2, Randomized, Double-blind, Placebo-controlled, 2-part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-6400 in Adult Healthy Volunteers and Multiple Dose ALN-6400 in Adult Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

89

Actual

Start

Nov 7, 2024

Primary completion

Jan 5, 2028

Study completion Jun 22, 2028

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Oct 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to: * evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers * evaluate the efficacy, safety, tolerability and PD of multiple doses of ALN-6400 in adult patients with HHT

Conditions

  • Hereditary Hemorrhagic Telangiectasia

Interventions

  • ALN-6400Drug

    ALN-6400 will be administered subcutaneously (SC)

  • PlaceboDrug

    Placebo will be administered subcutaneously (SC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Frequency of Adverse EventsTime frame: Up to Week 36
  2. Part B: Frequency of Adverse EventsTime frame: Up to Week 96

Locations

16 sites in 6 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Birmingham, Alabama

  • Clinical Trial Site

    Cypress, California

  • Clinical Trial Site

    Gainesville, Florida

  • Clinical Trial Site

    Indianapolis, Indiana

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Rochester, Minnesota

  • Clinical Trial Site

    St Louis, Missouri

  • Clinical Trial Site

    Chapel Hill, North Carolina

  • Clinical Trial Site

    Camperdown, Australia

  • Clinical Trial Site

    Parkville, Australia

  • Clinical Trial Site

    Mount Royal, Canada

  • Clinical Trial Site

    Toronto, Canada

  • Clinical Trial Site

    Bordeaux, France

  • Clinical Trial Site

    Bron, France

  • Clinical Trial Site

    Homburg, Germany

  • Clinical Trial Site

    L'Hospitalet de Llobregat, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.